Drug rep Bruce Boise, refused to follow company-ordered sales strategies to convince doctors to prescribe Cephalon's Actiq, Gabitril and Provigil drugs for unapproved ("off-label') uses because he was worried the sales practices were illegal and the "off-label" uses were dangerous for patients.
He and 3 other whistleblowers will receive a reward totaling $46 million for their information and the work on the case they did with their attorneys on the federal case and roughly an additional $11 million for the state cases.
More
Showing posts with label Cephalon. Show all posts
Showing posts with label Cephalon. Show all posts
Tuesday, September 30, 2008
Monday, September 29, 2008
Cephalon - $425 million: that's an expensive perc-a-pop!
Federal authorities have announced a $425 million civil settlement with Cephalon, who were charged with off-label drug marketing.Authorities say Cephalon marketed one of the drugs, Actiq, for maladies including migraines and injuries. The fentanyl lollipop is a highly addictive narcotic only approved for cancer pain.
Ed at Pharmalot has even more!
Wednesday, February 20, 2008
FTC crackdown on Big Pharma - FORTUNE explains
For years, Big Pharma has kept competition from generic drug makers at bay by essentially paying its would-be rivals to stay out of its business. Now government watchdogs have declared war on these financial deals - a move that could bring cheaper drugs to market faster while costing giant drug developers billions in lost revenue.
Just last week the Federal Trade Commission launched a high-profile battle against Cephalon, the maker of the blockbuster narcolepsy medication Provigil, over a $200 million payout it gave to four generic companies in exchange for an agreement not to develop a competing medication. In a lawsuit filed in federal court in Washington, D.C., the FTC claims that the deal violates antitrust law.
The deals behind the FTC crackdown have become increasingly common ever since Congress opened the door for generic drug competition in 1984. That's when a new federal law allowed generic drugmakers to challenge patents held by brand-name pharmaceutical companies in court. As these lawsuits grew in number, Big Pharma started to broker settlements whereby the generic companies agreed not to develop a competing drug in exchange for a onetime payment, often totaling millions of dollars.
The FTC says there have been 100 deals like this since 2004.
More
Just last week the Federal Trade Commission launched a high-profile battle against Cephalon, the maker of the blockbuster narcolepsy medication Provigil, over a $200 million payout it gave to four generic companies in exchange for an agreement not to develop a competing medication. In a lawsuit filed in federal court in Washington, D.C., the FTC claims that the deal violates antitrust law.
The deals behind the FTC crackdown have become increasingly common ever since Congress opened the door for generic drug competition in 1984. That's when a new federal law allowed generic drugmakers to challenge patents held by brand-name pharmaceutical companies in court. As these lawsuits grew in number, Big Pharma started to broker settlements whereby the generic companies agreed not to develop a competing drug in exchange for a onetime payment, often totaling millions of dollars.
The FTC says there have been 100 deals like this since 2004.
More
Subscribe to:
Posts (Atom)